RJ Hamster
Discover PMAX: Asia’s Under-the-Radar Market Leader.
A message from our partners at SmallCaps Daily
PMAX: The U.S. Investor’s Shortcut to Asia’s Explosive Capital Markets, Backed by Mandatory Compliance Demand and a Proven Hong Kong Infrastructure Platform.
Powell Max Limited (NASDAQ: PMAX) is more than a financial services provider—it’s the backbone of corporate reporting for Hong Kong’s listed companies and IPO candidates.Operating in a highly regulated ecosystem, PMAX handles the critical financial printing, prospectus design, bilingual translation, and electronic filing that companies must get right every time. With 24/7 operations and an integrated platform, PMAX ensures clients meet tight deadlines and avoid regulatory pitfalls, creating predictable demand for its services.
PMAX represents a way to get exposure to Asia’s multi-trillion-dollar equity marketswithout having to navigate foreign exchanges directly. The company’s recurring revenue streams, low leverage, and recently strengthened leadership and board make it poised to capitalize on IPOs and ongoing compliance-driven activity. In a sector where reliability and precision are everything, PMAXhas built an operational moat that U.S. investors can leverage for growth-oriented returns.
More Reading from MarketBeat Media
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
Reported by Nathan Reiff. Date Posted: 3/12/2026.
Key Points
- Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: 3 tickers just showed unusual early patterns. See the Trading Ideas report now. (From Trading Ideas)
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, several promising treatments have shown significant potential—and with that comes the possibility of substantial sales.
Two smaller biotech companies are riding strong share-price momentum thanks to their leading oncology medicines. Besides offering powerful therapeutic potential, these drugs could help the firms move beyond penny-stock or otherwise unstable status and potentially toward long-term profitability. In both cases, challenges remain, making these typical biotech investments high-risk ventures that could deliver outsized rewards for investors willing to take a chance.
Iovance’s Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle
BREAKING: A C$26M Company Just Responded to the Pentagon’s Call for Critical Minerals. (Ad)
One micro-cap subsea mining company just submitted a formal bid in response to a U.S. Defense Industrial Base Consortium solicitation to provide a reliable supply of Nickel to the United States. The DIBC, managed by Advanced Technology International on behalf of the DoW, issued this RPP in February 2026 targeting nickel, a critical mineral used in aircraft, missiles, semiconductors, and defense technologies—the Consortium provides non-dilutive financing for selected contractors, meaning potential government-backed capital without issuing new shares.
The urgency is not theoretical—China controls approximately 80% of global cobalt refining and 90% of rare earth processing and imposed defense-targeted export restrictions in December 2025. Management brings 25+ years of offshore experience from ConocoPhillips and BP, with roughly C$26 million market cap.View the full report here
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 slipped about 1%. That added to its year-to-date performance, with shares more than doubling. Still, with a consensus price target of $8.88, Wall Street expects more from IOVA—that target implies roughly 71% upside from current levels.
The main catalyst for Iovance’s move is its T-cell immunotherapy Amtagvi, which treats certain types of melanoma.
Amtagvi was approved in the United States for melanoma in 2024 and has been gaining momentum in sales, with potential approvals expected in the E.U., U.K., and elsewhere. When administered with Proleukin, the company’s IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. peak sales.
Amtagvi may have broader potential: it received FDA Fast Track Designation for non-small cell lung cancer and could be effective against other tumor types as well.
Some of Iovance’s outperformance this year also followed its Q4 2025 earnings report, released in late February, in which the company posted narrower-than-expected losses per share and reported $5 million in revenue. For the full year, revenue rose about 30% year-over-year.
Iovance remains a small-cap company (around $2 billion) and is still viewed as a penny stock, so analysts are cautious—roughly half of the company’s dozen analyst ratings are Hold or Sell. Beyond the usual risks for smaller biotechs, Amtagvi’s personalized, costly and complex manufacturing process is a material vulnerability; production and logistics challenges could limit profitability even as demand grows.
Massive Sales Growth for ImmunityBio’s Bladder Cancer Drug
While ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its year-to-date performance dwarfs Iovance’s—IBRX shares are up nearly 300% in 2026 alone. Analysts’ consensus target of $13.60 implies roughly 70% upside from the current price, even after the recent run-up.
Anktiva is ImmunityBio’s leading product and primary growth driver, approved for certain bladder cancers. In February, shares jumped after the E.U. regulator granted the drug conditional marketing authorization—another step in a series of global approvals.
Anktiva drove $113 million in sales last year, roughly a 700% year-over-year increase.
Like Amtagvi, Anktiva may have potential in other cancer types; ImmunityBio is actively exploring additional indications.
Despite the significant surge in recent quarters, IBRX remains a speculative and risky investment.
ImmunityBio reported a full-year net loss of $351 million for 2025 as R&D expenses remained high. Analysts are generally more bullish on this company than on Iovance—six of seven coverage analysts rate the shares a Buy or equivalent.
This email message is a paid advertisement provided by SmallCaps Daily, a third-party advertiser of MarketBeat. Why did I receive this email content?.
This message is a paid advertisement for Powell Max Limited (NASDAQ: PMAX) from SmallCaps Daily and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $14,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either SmallCaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Powell Max Limited (NASDAQ: PMAX) on Interactive Offers’ website for additional information about the relationship between Interactive Offers and Powell Max Limited (NASDAQ: PMAX).
If you need assistance with your newsletter, please contact our South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC.
345 North Reid Place, Sixth Floor, Sioux Falls, SD 57103. United States..
Today’s Featured Content: Elon Musk already made me a “wealthy man” (From The Oxford Club)
